Literature DB >> 23568206

Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model.

Laetitia Rodes1, Afshan Khan, Arghya Paul, Michael Coussa-Charley, Daniel Marinescu, Catherine Tomaro-Duchesneau, Wei Shao, Imen Kahouli, Satya Prakash.   

Abstract

Gut-derived lipopolysaccharides (LPS) are critical to the development and progression of chronic low-grade inflammation and metabolic diseases. In this study, the effects of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharide and inflammatory cytokine concentrations were evaluated using a human colonic microbiota model. Lactobacillus reuteri, L. rhamnosus, L. plantarum, Bifidobacterium animalis, B. bifidum, B. longum, and B. longum subsp. infantis were identified from the literature for their anti-inflammatory potential. Each bacterial culture was administered daily to a human colonic microbiota model during 14 days. Colonic lipopolysaccharides, and Gram-positive and negative bacteria were quantified. RAW 264.7 macrophage cells were stimulated with supernatant from the human colonic microbiota model. Concentrations of TNF-alpha, IL-1beta, and IL-4 cytokines were measured. Lipopolysaccharide concentrations were significantly reduced with the administration of B. bifidum (-46.45 +/- 5.65%), L. rhamnosus (-30.40 +/- 5.08%), B. longum (-42.50 +/- 1.28%), and B. longum subsp. infantis (-68.85 +/- 5.32%) (p < 0.05). Cell counts of Gram-negative and positive bacteria were distinctly affected by the probiotic administered. There was a probiotic strain-specific effect on immunomodulatory responses of RAW 264.7 macrophage cells. B. longum subsp. infantis demonstrated higher capacities to reduce TNF-alpha concentrations (-69.41 +/- 2.78%; p < 0.05) and to increase IL-4 concentrations (+16.50 +/- 0.59%; p < 0.05). Colonic lipopolysaccharides were significantly correlated with TNF-alpha and IL-1beta concentrations (p < 0.05). These findings suggest that specific probiotic bacteria, such as B. longum subsp. infantis, might decrease colonic lipopolysaccharide concentrations, which might reduce the proinflammatory tone. This study has noteworthy applications in the field of biotherapeutics for the prevention and/or treatment of inflammatory and metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568206     DOI: 10.4014/jmb.1205.05018

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  45 in total

1.  Gut-targeted immunonutrition boosting natural killer cell activity using Saccharomyces boulardii lysates in immuno-compromised healthy elderly subjects.

Authors:  Yasuhiro Naito; Francesco Marotta; Makoto K Kantah; Nicola Zerbinati; Almagul Kushugulova; Zhaxybay Zhumadilov; Nicola Illuzzi; Chiara Sapienza; Hiroshi Takadanohara; Riyichi Kobayashi; Roberto Catanzaro
Journal:  Rejuvenation Res       Date:  2014-04-11       Impact factor: 4.663

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

3.  Bifidobacterium--friend or foe? A case of urinary tract infection with Bifidobacterium species.

Authors:  Poonam Pathak; Cheryl Trilligan; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2014-09-24

4.  Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis.

Authors:  Saman Khalesi; David Wayne Johnson; Katrin Campbell; Susan Williams; Andrew Fenning; Sonia Saluja; Christopher Irwin
Journal:  Eur J Nutr       Date:  2017-11-08       Impact factor: 5.614

Review 5.  Irritable bowel syndrome: a gut microbiota-related disorder?

Authors:  Yogesh Bhattarai; David A Muniz Pedrogo; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-23       Impact factor: 4.052

Review 6.  Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.

Authors:  Nazanin Momeni Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Mohammad Hosein Farzaei; André M Marques; Amir Hossein Abdolghaffari
Journal:  Daru       Date:  2019-07-04       Impact factor: 3.117

Review 7.  Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.

Authors:  Susan Westfall; Nikita Lomis; Imen Kahouli; Si Yuan Dia; Surya Pratap Singh; Satya Prakash
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

8.  Bacillus amyloliquefaciens BLCC1-0238 Alone or in Combination with Mannan-Oligosaccharides Alleviates Subclinical Necrotic Enteritis in Broilers.

Authors:  Hongna Zhang; Yufa Zhou; Hong Xu; Chao Liang; Zhenzhen Zhai
Journal:  Probiotics Antimicrob Proteins       Date:  2021-10-08       Impact factor: 4.609

9.  Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease.

Authors:  David Briskey; Mandy Heritage; Lesley-Anne Jaskowski; Jonathan Peake; Glenda Gobe; V Nathan Subramaniam; Darrell Crawford; Catherine Campbell; Luis Vitetta
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

Review 10.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.